SURVYR

NAUT

Nautilus Biotechnology, Inc.
$2.89
+$0.45 (18.44%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-38%+27%+91%+155%+219%Oct 2025Oct 2026Apr 202652w high $4.3152w low $0.84
NAUTSPY
Wall St. Highest PT $4.00 (+38.4%) Wall St. Avg PT $3.83 (+32.6%)
$1$2$2$3$4POC $2Hi $4Avg $4
Underwater Drawdown %Max DD -78.4%Current -26.8%
0.0%-78.4%
Relative Strength vs SPY+100.5% vs SPYOutperforming
+226%0%-226%
1W
+$0.34 (13.33%)
1M
+$1.93 (200.10%)
3M
+$1.69 (140.83%)
6M
+$0.30 (11.58%)
YTD
+$0.94 (48.21%)
1Y
+$1.54 (114.07%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
3 analysts · mean score 1.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$2.89
Average target$3.83
+$0.94 (+32.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$3.50
Median$3.83
High$4.00
12-month Wall Street target range
Recent analyst rating changes · 8
Initiated
2026-09-29 · Roth Capital started covering NAUT at Buy
Initiated
2026-09-09 · Leerink Partners started covering NAUT at Outperform
Reiterated
2026-02-27 · Guggenheim reiterated Buy on NAUT
Downgrade
2024-12-05 · Goldman Sachs downgraded NAUT from Neutral to Sell
Initiated
2024-06-27 · Guggenheim started covering NAUT at Buy
Reiterated
2023-08-03 · Morgan Stanley reiterated Equal-Weight on NAUT
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$351.9M
P/E (next 12 months, estimated)-3.7
52-week range$0.84 – $4.31
Dividend yieldNo dividend
Analyst consensusStrong Buy (3)
Average analyst price target$3.83 (+33%)

What they do

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for NAUT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

NAUT earningsNext report in -1 days
Next report · quarter Sep 2026
Tue Oct 27, 2026Before the open
EPS consensus–
Revenue consensus$206.2K 4 analysts
Last 4 quarters · EPS vs estimate
Jul 28, 2026-$0.11est -$0.14+21.4%Above estimates
Apr 28, 2026-$0.12est -$0.14+17.2%Above estimates
Feb 26, 2026-$0.11est -$0.14+21.4%Above estimates
Oct 28, 2025-$0.11est -$0.15+26.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 12:05:00 ET
24-1025-0225-0425-0725-1026-0226-0426-07-0.170.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$10.0K–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
Nautilus (NAUT) Q3 2026 Earnings Call Transcript
Nasdaq · Oct 27
Rating changes
Initiated
2026-09-29 · Roth Capital started covering NAUT at Buy
Initiated
2026-09-09 · Leerink Partners started covering NAUT at Outperform
Reiterated
2026-02-27 · Guggenheim reiterated Buy on NAUT
Downgrade
2024-12-05 · Goldman Sachs downgraded NAUT from Neutral to Sell
Initiated
2024-06-27 · Guggenheim started covering NAUT at Buy
Reiterated
2023-08-03 · Morgan Stanley reiterated Equal-Weight on NAUT

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 12:05:00 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026